Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?

  title={Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?},
  author={Nina P Paynter and Paul M. Ridker and Daniel I. Chasman},
  journal={Circulation research},
  volume={118 4},
In this review, we lay out 3 areas currently being evaluated for incorporation of genetic information into clinical practice related to atherosclerosis. The first, familial hypercholesterolemia, is the clearest case for utility of genetic testing in diagnosis and potentially guiding treatment. Already in use for confirmatory testing of familial hypercholesterolemia and for cascade screening of relatives, genetic testing is likely to expand to help establish diagnoses and facilitate research… 

Figures from this paper

Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine.

The potential of genetic screening for Atherosclerosis prevention is discussed and the potential target of 17 genes responsible for monogenic dyslipidaemias associated with atherosclerosis is presented.

Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis

Testing for a 27-single-nucleotide polymorphism cGRS is generally not a cost-effective approach for targeting statin therapy in the primary prevention of ASCVD for low- to intermediate-risk patients.

Application of Single-Nucleotide Polymorphism-Related Risk Estimates in Identification of Increased Genetic Susceptibility to Cardiovascular Diseases: A Literature Review

The studies suggest that an SNP is a poor estimator of individual risk, whereas an individual’s genetic profile combined with non-genetic risk factors may better predict CVD risk among certain patient subgroups.

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

Recent large sample-size studies that have been validated in a separate cohort in most cases are focused on, highlighting the prognostic ability of risk markers related to atherosclerosis, thrombosis, inflammation, cardiac injury, and fibrosis.

Impact of Providing Future Cardiovascular Risk Based on Genetic Testing on Low-Density Lipoprotein Cholesterol in Patients with Familial Hypercholesterolemia (GenTLe-FH): A Randomized Wait-list Controlled Open-Label Trial

In addition to standard FH care, providing future cardiovascular risk based on genetic testing can further reduce plasma LDL-C levels, particularly among FH causal variant carriers.

Nontraditional Cardiovascular Biomarkers and Risk Factors: Rationale and Future Perspectives

Vitamin D and bone turnover biomarkers, hepatitis C virus, and psycho-emotional factors that may reflect alternative pathways over those generally considered for atherosclerosis are discussed, which could facilitate a more accurate assessment of CV risk stratification if incorporated in the current risk assessment algorithms.

Genetics of coronary artery disease: discovery, biology and clinical translation

Genetic testing could enable precision medicine approaches by identifying subgroups of patients at increased risk of coronary artery disease or those with a specific driving pathophysiology in whom a therapeutic or preventive approach would be most useful.

Strengthening the reporting of genetic risk prediction studies: the GRIPS statement.

With increasing numbers of discovered genetic markers that can be used in future genetic risk prediction studies, it is crucial to enhance the quality of the reporting of these studies, since valid interpretation could be compromised by the lack of reporting of key information.

Use of genetic data to guide therapy in arterial disease

This review focuses on the genetic determinants of commonly used platelet antagonists and anticoagulants including aspirin, clopidogrel, dabigatran, and warfarin and explores the clinical translation of pharmacogenetics in the management of patients with CVD.

Genome-based prediction of common diseases: advances and prospects.

It is argued that new gene discoveries may not evidently improve the prediction of common diseases to a degree that it will change the management of individuals at increased risk.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

The use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach.

Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.

Differences in study designs, variable methods for assessing pharmacologic exposures, heterogeneous phenotypes, and small sample sizes coupled with a short duration of follow-up in many studies account for a large portion of these inconsistencies.

Multilocus Genetic Risk Scores for Coronary Heart Disease Prediction

The results indicate that genetic information could be of some clinical value for prediction of CHD, although further studies are needed to address aspects, such as feasibility, ethics, and cost efficiency of genetic profiling in the primary prevention setting.

Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries.

A 6-SNP LDL-C score consistently distinguishes FH/M- patients from healthy individuals and indicates a >95% likelihood of a polygenic explanation of their increased cholesterol-raising alleles.

LDL cholesterol: controversies and future therapeutic directions